Clinical trial · Observational
Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.
NCT04284631CI-TRIAL-00044394completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess alterations of EGFR\& Her2neu expression in primary ovarian high grade serous carcinoma and its correlation with other clinicopathological parameters
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- EGFR& Her2neu expression to the grade of ovarian serous carcinoma
- timeFrame
- 2 years
- description
- EGFR\& Her2neu expression in primary ovarian high grade serous carcinoma
- measure
- EGFR& Her2neu expression in primary ovarian serous carcinoma to prognosis
- timeFrame
- 5 years
- description
- Expression of EGFR \& Her2neu in primary ovarian cancer to cancer free period
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients with primary ovarian cancer Exclusion Criteria: * patients with secondary ovarian cancer
References
Publications (0)
Data not yet available
No reference posted for this study.